Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Satoshi Nomura, Keisuke Aoe, Makoto Nishio, Toyoaki Hida, Takeshi Tajima, Kadoaki Ohashi, Takashi Seto, Masayuki Takeda, Sanae Moizumi, Shunichi Sugawara
Publikováno v:
Cancer Science
MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable saf
Autor:
Mie Suzuki, Hidetoshi Hayashi, Makoto Nishio, Gerson Peltz, Takashi Nagasawa, Toyoaki Hida, Takashi Seto, Kei Fukuhara, Masayuki Ohkura, Miyako Satouchi, Yasushi Goto, Holger Thurm, Masahiro Morise, Naoyuki Nogami, Toshiaki Takahashi, Seiji Niho, Jun Sakakibara-Konishi
Publikováno v:
Cancer Science
Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multina
Autor:
Kazuhiro Asada, Joe Shindoh, Kazuyoshi Imaizumi, Masato Karayama, Akihito Kubo, Yuko Oya, Kenta Murotani, Eiji Kunii, Takafumi Suda, Sayako Morikawa, Tatsuya Yoshida, Toyoaki Hida, Takeshi Tsuda, Kentaro Ito, Kosuke Takahashi, Teppei Yamagichi, Tomoki Kimura, Shunsaku Hayai, Osamu Hataji, Hirokazu Taniguchi, Takashi Abe, Naoki Inui, Motoyasu Okuno
Publikováno v:
Cancer Science
We constructed a data set of EGFR‐mutant non–small‐cell lung carcinoma (NSCLC) patients, and compared the overall survival of first‐generation (1G), and second‐generation (2G) EGFR‐tyrosine kinase inhibitors (TKIs) in clinical practice us
Autor:
Toyoaki Hida, Teppei Yamaguchi
Publikováno v:
J Thorac Dis
JAMA Oncol
JAMA Oncol
IMPORTANCE: Consolidative programmed death ligand-1 (PD-L) inhibition after chemoradiotherapy improves overall survival and progression-free survival (PFS) for stage III non–small cell lung cancer (NSCLC) and requires safety evaluation for incorpor
Autor:
Shiro Fujita, Katsutoshi Seto, Toyoaki Hida, Kenichi Okubo, Yoshitsugu Horio, Waki Hosoda, Katsuhiro Masago, Masataka Haneda, Hiroaki Kuroda
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 7, Pp 1827-1834 (2020)
Thoracic Cancer, Vol 11, Iss 7, Pp 1827-1834 (2020)
Background RNA‐based sequencing is considered ideal for detecting pathogenic fusion‐genes compared to DNA‐based assays and provides valuable information about the relative expression of driver genes. However, RNA from formalin‐fixed paraffin
Autor:
Geoffrey I. Shapiro, Liza C. Villaruz, Jeffrey W. Clark, Alexander Drilon, Gregory J. Riely, Danielle Murphy, Tiziana Usari, D. Ross Camidge, Miyako Satouchi, Paul K. Paik, Sherry Li, Mark M. Awad, Toyoaki Hida, Jared Weiss, Rebecca S. Heist, Hidetoshi Hayashi, Sherry C. Wang, Benjamin Solomon, Sai-Hong Ignatius Ou, Keith D. Wilner, Gregory A. Otterson
Publikováno v:
Nature medicine
MET exon 14 alterations are oncogenic drivers of non-small cell lung cancers (NSCLCs).1 These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition.2 Crizotinib is a multikinase inhibitor with potent act
Autor:
Junichi Shimizu, Waki Hosoda, Toyoaki Hida, Takeo Nakada, Takuya Matsui, Keita Nakanishi, Noriaki Sakakura, Harushi Ueno, Hiroaki Kuroda, Yuko Oya
Publikováno v:
Anticancer Research. 39:5789-5795
Background/aim Pulmonary pleomorphic carcinoma (PPC) is rare, and few studies have reported its features. We assessed the clinicopathological features, surgical outcomes, oncogenic status and programmed death-ligand 1 (PD-L1) expression of PPC. Patie
Autor:
Sarah L. Vowler, Makoto Nishio, Hiroshi Sakai, Tomonori Hirashima, Katsuyuki Kiura, Fumio Imamura, Tetsuya Mitsudomi, Kazuo Kasahara, Toyoaki Hida, Miyako Satouchi, Hirohiko Uchida, Isamu Okamoto, Terufumi Kato
Publikováno v:
Cancer Science
Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are the standard of care for non‐small‐cell lung cancer (NSCLC) patients harboring EGFR mutations. However, almost all patients develop resistance after approximately 1 y
Autor:
Koichi Goto, Mitsuhiro Takenoyama, Koji Takeda, Shinji Atagi, Hidehito Horinouchi, M. Nishio, Tomohide Tamura, Naoyuki Nogami, Kazuhiko Nakagawa, Tomonori Hirashima, Hideo Saka, Naoki Sumiyoshi, Hiroshi Isobe, Hiroshi Sakai, Miyako Satouchi, Toyoaki Hida, Toshiaki Takahashi, Hiroshi Tanaka, Koichi Minato, Makoto Maemondo, Nobuyuki Katakami
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previo